Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale.

Badrising UA, Henderson R, Reddel S, Corbett A, Liang C, Reardon K, Ghaoui R, Bulsara M, Brady S, Brusch A, Chan D, Coudert JD, Fairchild T, Jain G, Kiernan MC, Leonard D, Lloyd T, Schmidt J, McDermott MP, Sanders L, Lowe C, van der Kooi AJ, Weihl C, Mohassel P, Simpson M, Carroll A, Cooper I, Beer K, Hiscock K, Walters S, Panicker A, Doverty A, Heim A, van Heur-Neuman M, Benveniste O, Dimachkie MM, Needham M

Open source

DOI: 10.55563/clinexprheumatol/zvffa0
Published: 2025 Feb
Container: Clinical and experimental rheumatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.55563/clinexprheumatol/zvffa0,
  title = {Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale.},
  author = {Badrising UA and Henderson R and Reddel S and Corbett A and Liang C and Reardon K and Ghaoui R and Bulsara M and Brady S and Brusch A and Chan D and Coudert JD and Fairchild T and Jain G and Kiernan MC and Leonard D and Lloyd T and Schmidt J and McDermott MP and Sanders L and Lowe C and van der Kooi AJ and Weihl C and Mohassel P and Simpson M and Carroll A and Cooper I and Beer K and Hiscock K and Walters S and Panicker A and Doverty A and Heim A and van Heur-Neuman M and Benveniste O and Dimachkie MM and Needham M},
  year = {2025},
  journal = {Clinical and experimental rheumatology},
  doi = {10.55563/clinexprheumatol/zvffa0},
  url = {https://doi.org/10.55563/clinexprheumatol/zvffa0}
}

RIS

TY  - JOUR
TI  - Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale.
AU  - Badrising UA
AU  - Henderson R
AU  - Reddel S
AU  - Corbett A
AU  - Liang C
AU  - Reardon K
AU  - Ghaoui R
AU  - Bulsara M
AU  - Brady S
AU  - Brusch A
AU  - Chan D
AU  - Coudert JD
AU  - Fairchild T
AU  - Jain G
AU  - Kiernan MC
AU  - Leonard D
AU  - Lloyd T
AU  - Schmidt J
AU  - McDermott MP
AU  - Sanders L
AU  - Lowe C
AU  - van der Kooi AJ
AU  - Weihl C
AU  - Mohassel P
AU  - Simpson M
AU  - Carroll A
AU  - Cooper I
AU  - Beer K
AU  - Hiscock K
AU  - Walters S
AU  - Panicker A
AU  - Doverty A
AU  - Heim A
AU  - van Heur-Neuman M
AU  - Benveniste O
AU  - Dimachkie MM
AU  - Needham M
PY  - 2025
JO  - Clinical and experimental rheumatology
DO  - 10.55563/clinexprheumatol/zvffa0
UR  - https://doi.org/10.55563/clinexprheumatol/zvffa0
ER  -

APA

UA, B., R, H., S, R., A, C., C, L., K, R., R, G., M, B., S, B., A, B., D, C., JD, C., T, F., G, J., MC, K., D, L., T, L., J, S., MP, M., L, S., C, L., AJ, V. D. K., C, W., P, M., M, S., A, C., I, C., K, B., K, H., S, W., A, P., A, D., A, H., M, V. H., O, B., MM, D., & M, N. (2025). Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale.. Clinical and experimental rheumatology. https://doi.org/10.55563/clinexprheumatol/zvffa0

Source records

pubmed · retrieved 2026-09-26T16:15:51.914Z